Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, Biocon has informed that the US FDA conducted a pre approval inspection of its new Oral Solid Dosage Forms manufacturing facility at Biocon Park/ Bengaluru/ from Nov 05- Nov 09/ 2018. The audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects its strong commitment to quality and cGMP compliance -Company Spokesperson.
The above information is a part of company’s filings submitted to BSE.